Pedal the Cause: Annual Fundraiser for Cancer Research

RoadBikingv1Pedal the Cause is an annual cycling fundraiser in which 100 percent of the net proceeds stay in San Diego to benefit cancer research at the three local National Cancer Institute-designated cancer centers, UC San Diego Moores Cancer Center, Sanford-Burnham Medical Research Institute and the Salk Institute for Biological Studies. The goal is to fund research that may lead to a cure for cancer.

The third annual event will take place September 18-20, 2015, featuring courses for any riding ability, from 10 miles up to a two-day ride. Participants can register to ride, become a virtual rider, or volunteer. Register at  http://sandiego.pedalthecause.org

BCRF Collaborators Make a Strong Showing

“Cancer research is moving at an accelerated pace but there are still many unanswered questions that our team is trying to answer through innovative science,” said Scott Lippman, MD, director of Moores Cancer Center at UC San Diego Health. “The NCI Outstanding Investigator Award provides important additional resources that will help us realize scientific discoveries best accomplished at a comprehensive cancer center.”

Read the whole article here!

FDA Approves First Biosimilar Drug

This spring the Food and Drug Administration approved the first biosimilar drug for use in the United States, opening the regulatory door to lower-cost versions of a class of pharmaceuticals called biologics. The drug, Zarzio, helps patients receiving chemotherapy make white blood cells, preventing infections common among cancer patients. It is considered therapeutically equivalent to the existing biologic, Neupogen.  

So why is this important? READ MOREneupogen-16148_3

2015 CRC – BCRF Patient Meeting

In honor of Miles Pendleton, a CLL patient and advocate, the CLL Research Consortium and the Blood Cancer Research Fund, hosted a patient education and empowerment meeting.  The meeting took place at UC San Diego Moores Cancer Center, in La Jolla, California.  We will covered a wide-range of topics: from early stage CLL, prognosis, targeted therapies, to forming your own CLL team. By the end of the meeting the participants had a clear understanding of the new research developments, treatments types, and how to address needs beyond just treatment of CLL. 

CRC2015 Panel

We are now in the process of posting videos of each of our wonderful speakers!  Keep coming back to this page for the complete listing of speakers! Click on the name of the speaker and you’ll be taken to the YouTube posting!

Cirmtuzumab: Here About the Promising New Therapy

Researchers at UC San Diego are developing a new drug to treat CLL. The drug, cirmutuzumab, is an antibody designed to attach to a protein on the surface of CLL cells. Researchers hope that this process will block cancerous cell growth and survival. Right now, cirmtuzumab is being tested for its safety and effectiveness in humans in a Phase One clinical trial.  “A brand new way to target and kill blood cancer,” WNDU, features Thomas Kipps, MD, PhD.
(Source: http://www.utsandiego.com/news/2014/sep/17/ucsd-leukemia-cll-trial-kipps-cirm/, https://clinicaltrials.gov/ct2/show/NCT02222688?term=cirmtuzumab&rank=1 )

And see: http://medicalxpress.com/news/2014-10-first-in-human-trials-therapeutic-stem-cell.html

Wtumblr_nl44wnTdjK1qievavo1_500AAY

 

The Role of a NOTCH1 Mutation for CLL Patients

The Promise of Immuno-Oncology to Treat CLL

From Patient Power:

Could a patient’s own immune system be sparked to fight chronic lymphocytic leukemia (CLL)? Research into immunotherapy—or immuno-oncology—CLL treatment approaches is currently underway and creating buzz. Dr. Thomas Kipps, a leading CLL expert, explores immuno-oncology treatments in development, how they work and why he finds the research “truly exciting.”

http://www.patientpower.info/video/ash-coverage-the-promise-of-immuno-oncology-to-treat-cll